We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts. In this article, we are going to ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

Novo Nordisk revealed a stunning increase in pollution amid plans to boost production of its popular weight loss drug Wegovy.

Dividend stocks have been a reliable cornerstone for those who want to anchor their portfolios when markets get shaky. These ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

President Trump has announced sweeping tariffs on several countries. Novo Nordisk and Smith & Nephew may be the most at risk ...

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

Jefferies analyst Lucy Codrington maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK415.00.

Hims & Hers Health ( HIMS 0.37%) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous ...

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and ...